Inhibition of BcR signaling or intrinsic apoptotic pathways by contemporary targeted therapies has shown significant clinical efficacy and prolonged progression-free and overall survival in poor-risk patients with CLL carrying TP53 aberrations or unmutated IGHV genes (26–29). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.